Elanco (ELAN)

Executive Summary

Elanco is a leading global animal health company with a portfolio of innovative pharmaceuticals, biologics, and digital solutions for companion animals and livestock. The company has a strong heritage of over 70 years and operates in more than 90 countries, holding market-leading brands such as Credelio, Seresto, and Advantage. Elanco's focus on advancing animal health through science positions it well in the growing pet care and livestock productivity markets. The company's strategic initiatives include expanding its product portfolio through internal R&D and acquisitions, as well as leveraging digital health technologies. Despite facing headwinds from generic competition and pricing pressures, Elanco's diversified business and commitment to innovation underpin its long-term growth potential. Recent efforts to streamline operations and reduce debt have improved financial flexibility, enabling investments in high-growth areas.

Upcoming Catalysts (preview)

• 2025 H2Launch of new parasiticide products for companion animals70% success
• 2026 H1Potential FDA approval for new livestock vaccine60% success
• TBDPartnership or acquisition in digital health or diagnostics50% success